Beltzig L - Search Results

1

Cytotoxic, Genotoxic and Senolytic Potential of Native and Micellar Curcumin.

Beltzig L, Frumkina A, Schwarzenbach C, Kaina B. Beltzig L, et al. Nutrients. 2021 Jul 13;13(7):2385. doi: 10.3390/nu13072385. Nutrients. 2021. PMID: 34371895 Free PMC article.

2

Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells.

Kaina B, Beltzig L, Piee-Staffa A, Haas B. Kaina B, et al. Among authors: beltzig l. Int J Mol Sci. 2020 Sep 23;21(19):7006. doi: 10.3390/ijms21197006. Int J Mol Sci. 2020. PMID: 32977591 Free PMC article.

3

Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses.

Stratenwerth B, Geisen SM, He Y, Beltzig L, Sturla SJ, Kaina B. Stratenwerth B, et al. Among authors: beltzig l. Mol Cancer Ther. 2021 Oct;20(10):1789-1799. doi: 10.1158/1535-7163.MCT-21-0228. Epub 2021 Jul 12. Mol Cancer Ther. 2021. PMID: 34253592 Free PMC article.

4

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment.

Schwarzenbach C, Tatsch L, Brandstetter Vilar J, Rasenberger B, Beltzig L, Kaina B, Tomicic MT, Christmann M. Schwarzenbach C, et al. Among authors: beltzig l. Cancers (Basel). 2021 Jul 17;13(14):3585. doi: 10.3390/cancers13143585. Cancers (Basel). 2021. PMID: 34298797 Free PMC article.

5

Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells.

Beltzig L, Stratenwerth B, Kaina B. Beltzig L, et al. Cancers (Basel). 2021 Dec 14;13(24):6287. doi: 10.3390/cancers13246287. Cancers (Basel). 2021. PMID: 34944906 Free PMC article.

6

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.

Beltzig L, Christmann M, Kaina B. Beltzig L, et al. Cells. 2022 Aug 19;11(16):2588. doi: 10.3390/cells11162588. Cells. 2022. PMID: 36010664 Free PMC article.

7

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells.

Beltzig L, Schwarzenbach C, Leukel P, Frauenknecht KBM, Sommer C, Tancredi A, Hegi ME, Christmann M, Kaina B. Beltzig L, et al. Cancers (Basel). 2022 Apr 29;14(9):2233. doi: 10.3390/cancers14092233. Cancers (Basel). 2022. PMID: 35565362 Free PMC article.

8

Temozolomide - Just a Radiosensitizer?

Kaina B, Beltzig L, Strik H. Kaina B, et al. Among authors: beltzig l. Front Oncol. 2022 Jun 16;12:912821. doi: 10.3389/fonc.2022.912821. eCollection 2022. Front Oncol. 2022. PMID: 35785203 Free PMC article.

9

Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma Cells.

Beltzig L, Christmann M, Dobreanu M, Kaina B. Beltzig L, et al. Anticancer Res. 2024 Mar;44(3):901-910. doi: 10.21873/anticanres.16884. Anticancer Res. 2024. PMID: 38423634

10

Generation of therapeutic antisera for emerging viral infections.

Schmidt R, Beltzig LC, Sawatsky B, Dolnik O, Dietzel E, Krähling V, Volz A, Sutter G, Becker S, von Messling V. Schmidt R, et al. Among authors: beltzig lc. NPJ Vaccines. 2018 Oct 5;3:42. doi: 10.1038/s41541-018-0082-4. eCollection 2018. NPJ Vaccines. 2018. PMID: 30323953 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

10 results

Search Page